



Cardioneuroablation for cardioinhibitory syncope Ready to replace pacing?

Chiara Valeriano, MD

Electrophysiology Fellow

Cardiovascular center OLV Hospital

Aalst, Belgium


Case presentation

- 55 y-o woman
- Diabetes, dyslipidaemia and previous hysterectomy due to endometriosis
- Recurrent syncopal episodes despite lifestyle measures (>2/year since the age of 30)

Risk stratification

- Long history of recurrent syncope mostly associated with prodromes
- No structural heart disease
- Normal examination
- Normal ECG

Low-risk



ILR is indicated in an early phase of evaluation in patients with recurrent syncope of uncertain origin, absence of high-risk criteria and a high likelihood of recurrence within the battery life of the device


I

A

After six months

New syncope

- ILR: progressive sinus bradycardia followed by **sinus arrest > 10 sec**



Cardiac pacing should be considered to reduce syncopal recurrences in patients aged >40 years, with spontaneous documented symptomatic asystolic pause(s) >3 s or asymptomatic pause(s) >6 s due to sinus arrest, AV block, or the combination of the two

IIa

B

Brignole M et al. Eur Heart J. 2018;39(21):1883–948

ISSUE-3 trial:


- 57% relative risk reduction
- 25% recurrence
- 5% complication

Despite detailed discussion with the patient and her family, the patient **refused pacemaker implantation**




Cardioneuroablation

Definition: to interrupt/blunt the cardioinhibitory reflex by eliminating post-ganglionic parasympathetic neurons in the atrial wall and ganglionated plexi



Chiou CW, Eble JN, Zipes DP; Circ, 1997;95:2573e84


- Ganglion A: **SVC-AoGP**
- Ganglion B: **RSGP** and **RIGP**
- Ganglion C: **PMLGP**



- Very susceptible to endocardial ablation
- Reinnervation less likely

How to localize GPs

1. Spectral EGM analysis



Limitations:

- The whole atrial endocardium needs to be scrutinized using computer-aided mapping

2. High-frequency stimulation


(20 Hz, 10-20 V, pulse width ms)



Limitations:

- GA
- Inadvertent AF induction
- No consensus on the best protocols and criteria to define VR


3. Anatomical approach



Limitations:

- Longer ablation time
- Unspecific

4. Anatomical + EGMs guided



Atropine test

How to perform

- 0.04mg/kg with continuous ECG recording for 30 min
- At least 24 hours before the procedure


Positive response

- SR increase of $\geq 25\%$ or a SR ≥ 90 bpm in the first 20 min after infusion


Why it's important?

- Good patient selection
- Define our clinical endpoint, post-atropine SR will set our target after ablation

Basal




HR 65 bpm
RR 920 ms




HR increase of 35%
Final HR of 100 bpm





Atropine 3mg (5 minutes later)



HR 100 bpm
RR 600 ms




Our workflow



- GA
- Double echo-guided puncture of the right femoral vein
- Single transseptal puncture under fluoroscopic and ultrasound guide
- 3D-RA of the left atrium, integration into 3D mapping and navigation system (CARTO), FAM of the right atrium



Ablation targets



1. SVC-AoGP

2. RSGP

3. PMLGP



HAFE

- number of deflections ≥ 4
- amplitude ≥ 0.7 mV
- duration ≥ 40 ms


Lellouche N. et al, JACC, 2007;50:1324–31

- The complete elimination of atrial EGMs (<0.1 mV) in targeted regions

Ablation procedure



Clinical targets and follow up



Pre-ablation

Post-ablation

RR 1100 (HR 55)
CSNRT 400
WCL 430

RR 700 (HR 85)
CSNRT 200
WCL 370

Clinical endpoints:

- Negative response to atropine test repeated 30 minutes after ablation
- Achievement of 75% of pre-ablation atropine test HR

1 year later

Asymptomatic
ILR analysis: no bradycardia, no asystole



Thanks for your attention

Contact info



@ChiaraValeriano



chiara.valeriano91@gmail.com